Guanhao Bio is expected to slightly expand revenue in the first quarter to participate in the research and development of new crown vaccines

Guanhao Bio is expected to slightly expand revenue in the first quarter to participate in the research and development of new crown vaccines

Guanhao Bio is expected to slightly expand revenue in the first quarter to participate in the research and development of new crown vaccines
On April 7, Guanhao Bio released the first quarter results forecast. Due to the epidemic, the company’s revenue is expected to be offset by 0-15%, which is 90 million yuan -1.100 million yuan.At the same time, due to the reduction of short-term market expenditures of the sales department and the reduction of sales expenses, the company actively responded to cost reduction and efficiency increase, and the management expenses caused by the report also dropped significantly.Therefore, Guanhao Bio’s first quarter net profit is expected to be 10 million to 12 million yuan, an annual increase of 0% -20%.Focusing on the fields of regenerative medicine and life-health-related industries, Guanhao Bio has the country’s only “National Engineering Laboratory for Regenerative Medical Implantable Devices” and is the national high-tech industrialization demonstration base for regenerative biofilms.(Spine) membrane patch is the first brand in the domestic meningeal market.On February 3, Guanhao Bio announced that the company and the US shareholding company announced the “Framework Agreement of Intent for Cooperation in Nucleic Acid Vaccine Project”, and plans to develop a new pneumonia coronavirus mRNA vaccine (Z-VacciRNA) research and clinical project.Invested in the first phase of research and development, ZYTherapeuticsInc.Responsible for research and development to carry out “ZY nucleic acid vaccine project”.Editor Yue Qingxiu proofreading Wang Xin